Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. This coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
According to the company, Epi+Gen CHD evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.
This announcement is significant because it brings advanced, AI-driven diagnostic tools to a broader patient population, potentially improving early detection and management of coronary heart disease—a leading cause of death worldwide. The partnership with Atlas Healthcare Physicians, which serves managed care populations in two of California’s most populous counties, could set a precedent for other independent physician associations to adopt similar precision medicine approaches.
For Cardio Diagnostics, this coverage expansion represents a step toward commercializing its proprietary AI-driven Integrated Genetic-Epigenetic Engine, which aims to make cardiovascular disease prevention, detection, and management more accessible and personalized. The company’s tests are designed to fill a gap in traditional cardiovascular risk assessment by integrating genetic and epigenetic markers.
The move also highlights a growing trend in healthcare: the shift from one-size-fits-all diagnostics to precision medicine that tailors treatment to individual molecular profiles. For patients, this could mean earlier intervention and more effective management of heart disease, potentially reducing the burden on healthcare systems.
More information about Cardio Diagnostics and its latest updates can be found in the company’s newsroom at https://nnw.fm/CDIO.
